IL15 and neoplasm: (113) found that IL-15 hyper-agonist receptor-linker -IL-15 (RLI) could limit tumor growth in the early stage of colorectal cancer and the combined use of PD-1 inhibitors had a higher activation rate of CD8+ TILs in colorectal cancer compared with PD-1 inhibitors or RLI alone, but had no significant inhibition or CD8+ TILs activation for advanced colorectal cancer, which was consistent with T cell exhaustion.